Biological response genes after single dose administration of interferon β-1b to healthy male volunteers
暂无分享,去创建一个
J. Reischl | S. Stürzebecher | R. Sandbrink | J. Heubach | J. Hilpert | J. Beekman | David Bauer | S. Schwenke | K. Kowal | Johannes Lampe
[1] B. Williams,et al. Novel interferon‐β‐induced gene expression in peripheral blood cells , 2007, Journal of leukocyte biology.
[2] Ludwig Kappos,et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study , 2007, The Lancet.
[3] E. Waubant,et al. Identification of short-term pharmacodynamic effects of interferon-beta-1a in multiple sclerosis subjects with broad- based phenotypic profiling , 2007, Journal of Neuroimmunology.
[4] W. A. LaFramboise,et al. Gene expression changes in peripheral blood mononuclear cells from multiple sclerosis patients undergoing β-interferon therapy , 2007, Journal of the Neurological Sciences.
[5] J. Justesen,et al. The human 2'-5'oligoadenylate synthetase family: unique interferon-inducible enzymes catalyzing 2'-5' instead of 3'-5' phosphodiester bond formation. , 2007, Biochimie.
[6] G. Salvesen,et al. The apoptosome: signalling platform of cell death , 2007, Nature Reviews Molecular Cell Biology.
[7] Parvin Mousavi,et al. Genome-Wide Network Analysis Reveals the Global Properties of IFN-β Immediate Transcriptional Effects in Humans12 , 2007, The Journal of Immunology.
[8] L. Kappos,et al. Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies , 2007, Journal of Neurology.
[9] C. Scagnolari,et al. Expression of biomarkers of interferon type I in patients suffering from chronic diseases , 2007, Clinical and experimental immunology.
[10] P. Kloetzel,et al. Virus-induced type I IFN stimulates generation of immunoproteasomes at the site of infection. , 2006, The Journal of clinical investigation.
[11] J. De Keyser,et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes , 2006, Neurology.
[12] R. Ransohoff,et al. Determinants of CCL5-driven mononuclear cell migration across the blood–brain barrier. Implications for therapeutically modulating neuroinflammation , 2006, Journal of Neuroimmunology.
[13] M. Wolman,et al. Repulsion or adhesion: receptors make the call. , 2006, Current opinion in cell biology.
[14] M. Ramanathan,et al. Dynamics of interferon-β modulated mRNA biomarkers in multiple sclerosis patients with anti-interferon-β neutralizing antibodies , 2006, Journal of Neuroimmunology.
[15] A. Takaoka,et al. Interferon signalling network in innate defence , 2006, Cellular microbiology.
[16] Takashi Yamamura,et al. Microarray analysis identifies a set of CXCR3 and CCR2 ligand chemokines as early IFNβ-responsive genes in peripheral blood lymphocytes in vitro: an implication for IFNβ-related adverse effects in multiple sclerosis , 2006, BMC neurology.
[17] Arthur Weiss,et al. Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation , 2004, Oncogene.
[18] A. Rivett,et al. Proteasome function in antigen presentation: immunoproteasome complexes, Peptide production, and interactions with viral proteins. , 2004, Current protein & peptide science.
[19] F. Bagnato,et al. Beta-2 microglobulin and neopterin as markers of disease activity in multiple sclerosis , 2003, Neurological Sciences.
[20] A. Bertolotto,et al. Measurement of MxA mRNA or protein as a biomarker of IFNβ bioactivity , 2003, Neurology.
[21] D. Ryglewicz,et al. Factors predicting early stroke fatality in Poland. Preliminary report of the Polish National Stroke Registry , 2003, Neurological Sciences.
[22] Murali Ramanathan,et al. Genomic Effects of IFN-β in Multiple Sclerosis Patients 1 , 2003, The Journal of Immunology.
[23] R. Mayeux,et al. Parkinsonian signs in older people , 2003, Neurology.
[24] D. Fuchs,et al. Potential role of immune system activation-associated production of neopterin derivatives in humans , 2003, Inflammation Research.
[25] J. Hidalgo,et al. Retracted: Treatment with metallothionein prevents demyelination and axonal damage and increases oligodendrocyte precursors and tissue repair during experimental autoimmune encephalomyelitis , 2003, Journal of neuroscience research.
[26] L. Staudt,et al. Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis. , 2003, Brain : a journal of neurology.
[27] Wei-Min Liu,et al. Analysis of high density expression microarrays with signed-rank call algorithms , 2002, Bioinform..
[28] Uwe Oelmueller,et al. Stabilization of mRNA expression in whole blood samples. , 2002, Clinical chemistry.
[29] B. Weir,et al. A systematic statistical linear modeling approach to oligonucleotide array experiments. , 2002, Mathematical biosciences.
[30] Thomas D. Schmittgen,et al. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.
[31] X. Montalban,et al. Altered inflammatory response and increased neurodegeneration in metallothionein I+II deficient mice during experimental autoimmune encephalomyelitis , 2001, Journal of Neuroimmunology.
[32] L. Staudt,et al. Complex immunomodulatory effects of interferon‐β in multiple sclerosis include the upregulation of T helper 1‐associated marker genes , 2001, Annals of neurology.
[33] V. Appay,et al. RANTES: a versatile and controversial chemokine. , 2001, Trends in immunology.
[34] P. Tan,et al. Metallothionein 1E mRNA is highly expressed in oestrogen receptor-negative human invasive ductal breast cancer , 2000, British Journal of Cancer.
[35] M. Reindl,et al. A comparative study of the relative bioavailability of different interferon beta preparations , 2000, Neurology.
[36] R. Maibauer,et al. Pharmacodynamic comparison of single doses of IFN-beta1a and IFN-beta1b in healthy volunteers. , 1999, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[37] G. Williams,et al. Comparative study of the pharmacodynamic and pharmacologic effects of Betaseron and AVONEX. , 1998, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[38] P. Salmon,et al. Pharmacokinetics and pharmacodynamics of recombinant human interferon-beta in healthy male volunteers. , 1996, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[39] R. Littell. SAS System for Mixed Models , 1996 .
[40] B. Storer,et al. Pharmacodynamics of biological response in vivo after single and multiple doses of interferon-beta. , 1993, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.
[41] T. Schall. Biology of the RANTES/SIS cytokine family. , 1991, Cytokine.
[42] M. Aebi,et al. cDNA structures and regulation of two interferon-induced human Mx proteins , 1989, Molecular and cellular biology.
[43] R. Chung,et al. Metallothioneins I and II: neuroprotective significance during CNS pathology. , 2007, The international journal of biochemistry & cell biology.
[44] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .